We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
201
ADMA Biologics
ADMA
$2.04B
$595K 0.03%
+100,000
New +$700K
MRTX
202
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$586K 0.03%
107,235
+50,835
+90% +$810K
SLNO
203
DELISTED
Soleno Therapeutics
SLNO
$581K 0.03%
6,683
-391
-6% -$35.7K
RDUS
204
CALL
DELISTED
Radius Health, Inc.
RDUS
$577K 0.03%
+157
New +$5.54K
CBMXW
205
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$573K 0.03%
+855,171
New +$751K
LRMR icon
206
CALL
Larimar Therapeutics
LRMR
$398M
$557K 0.03%
78
-43
-36% -$3.4K
PRQR icon
207
ProQR Therapeutics
PRQR
$248M
$532K 0.03%
110,000
-39,934
-27% -$205K
ANTH
208
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$518K 0.03%
210
+191
+1,005% +$5.4K
HTWR
209
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$514K 0.03%
+89
New +$2.91K
NWBO
210
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$512K 0.03%
881,585
-2,435,934
-73% -$2.6M
ASMB icon
211
Assembly Biosciences
ASMB
$507M
$502K 0.03%
+7,530
New +$494K
RVNC
212
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$461K 0.02%
339
+37
+12% +$654
ATRS
213
DELISTED
Antares Pharma, Inc.
ATRS
$445K 0.02%
424,100
-351,112
-45% -$339K
RDUS
214
PUT
DELISTED
Radius Health, Inc.
RDUS
$441K 0.02%
+120
New +$4.24K
BNTC icon
215
Benitec Biopharma
BNTC
$408M
$438K 0.02%
1,355
-300
-18% -$119K
INSM icon
216
Insmed
INSM
$22.6B
$433K 0.02%
43,964
+8,097
+23% +$94.5K
VXX
217
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$414K 0.02%
+19
New +$4.74K
VYNT
218
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$397K 0.02%
1,331
+789
+146% +$277K
NERV icon
219
Minerva Neurosciences
NERV
$199M
$388K 0.02%
+4,750
New +$302K
BDSI
220
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$384K 0.02%
1,626
+714
+78% +$1.97K
QRHC icon
221
Quest Resource Holding
QRHC
$28.3M
$382K 0.02%
164,464
-102,025
-38% -$338K
RIGL icon
222
CALL
Rigel Pharmaceuticals
RIGL
$712M
$375K 0.02%
+168
New +$4.18K
PRTK
223
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$341K 0.02%
245
+59
+32% +$869
MDCO
224
PUT
DELISTED
Medicines Co
MDCO
$336K 0.02%
+100
New +$3.53K
SCON
225
DELISTED
Superconductor Technologies Inc.
SCON
$322K 0.02%
1,134
-689
-38% -$212K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.